ID | 30795 |
JaLCDOI | |
FullText URL | |
Author |
Matsuo, Keisuke
Ueoka, Hiroshi
Tabata, Masahiro
Kaken ID
researchmap
Shibayama, Takuo
Matsumura, Tadashi
Takigawa, Nagio
Hiraki, Shunkichi
Harada, Mine
|
Abstract | We have established an Adriamycin (ADM) -resistant small cell lung cancer (SCLC) cell line, SBC-3/ADM100, which shows multifactorial mechanisms of resistance to ADM, such as overexpression of P-glycoprotein, an enhanced detoxifying system and a decrease in topoisomerase II activity. In the present study, we confirmed that SBC-3/ADM 100 showed collateral sensitivity to methotrexate and TNP-351, a new antifolate, though this cell line showed a typical multidrug resistance (MDR) pattern. We also demonstrated a faster uptake and higher accumulation (1.3-fold) of TNP-351 in the SBC-3/ADM100 cells than those in the parent SBC-3 cells. These results explain one of the mechanisms for collateral sensitivity in the resistant cells. Furthermore, this cell line was found to have no cross-resistance to edatrexate and minimal cross-resistance to trimetrexate, 254-S (cisplatin analog), 5-fluorouracil and 4-hydroperoxyifosfamide. These drugs will have clinical importance in patients with SCLC who were previously treated with an ADM-containing regimen. Thus, antifolates, especially TNP-351 and edatrexate, can be expected to eradicate residual multidrug resistant SCLC cells selected by ADM. |
Keywords | Adriamycin-resistant cell line
antifolates
small cell lung cancer
|
Amo Type | Article
|
Publication Title |
Acta Medica Okayama
|
Published Date | 1997-06
|
Volume | volume51
|
Issue | issue3
|
Publisher | Okayama University Medical School
|
Start Page | 121
|
End Page | 127
|
ISSN | 0386-300X
|
NCID | AA00508441
|
Content Type |
Journal Article
|
language |
English
|
File Version | publisher
|
Refereed |
True
|
PubMed ID | |
Web of Science KeyUT |